See All Slides - tctmd.com

Slides

Presentation TCT 2013

Disparities in Care of Minorities and Patients with Depressed Socio-Economic Status: Implications of the Affordable Care Act

Presenter: A.J. Conrad Smith

October 31, 2013

Presentation TCT 2013

Public Reporting Is Coming: Are You Ready?

Presenter: Ralph Brindis

October 31, 2013

Presentation TCT 2013

Case #4 - Rescue PCI and MVD: which approach?

Presenter: Andreas Andreou

October 31, 2013

Presentation TCT 2013

Pro Position: Randomized Trial and Registry Data are Supporting That Direction!

Presenter: Josep Rodes-Cabau

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Technical Mastery of Left Main PCI: The Do's and The Don'ts

Presenter: Andrejs Erglis

October 31, 2013

Presentation TCT 2013

Case #4: Left Main CTO in Cardiogenic Shock

Presenter: Kais Battikh

October 31, 2013

Presentation TCT 2013

Case 1: Antegrade Dissection Reentry as Provisional Strategy for Failed Antegrade Wiring

Presenter: Elliot Smith

October 31, 2013

Presentation TCT 2013

Fish Oil and CHD Benefit: Is It the Dose, Type, Genetics or Blood Level? (EPA, DHA, FADS)

Presenter: H. Robert Superko

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Advertisement

Slides

Disparities in Care of Minorities and Patients with Depressed Socio-Economic Status: Implications of the Affordable Care Act

Public Reporting Is Coming: Are You Ready?

Case #4 - Rescue PCI and MVD: which approach?

Pro Position: Randomized Trial and Registry Data are Supporting That Direction!

Cangrelor Will Be the Answer for Most in the Acute Setting!

Technical Mastery of Left Main PCI: The Do's and The Don'ts

Case #4: Left Main CTO in Cardiogenic Shock

Case 1: Antegrade Dissection Reentry as Provisional Strategy for Failed Antegrade Wiring

Fish Oil and CHD Benefit: Is It the Dose, Type, Genetics or Blood Level? (EPA, DHA, FADS)

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content